68Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors
Akanksha Jain(Bhabha Atomic Research Centre), Ashutosh Dash(Bhabha Atomic Research Centre), Usha Pandey(Bhabha Atomic Research Centre), Haladhar Dev Sarma(Bhabha Atomic Research Centre), Mythili Kameswaran(Tata Memorial Hospital), Kumar Prabhash(Homi Bhabha National Institute)
Cited by 20
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
|Journal of Clinical Oncology|2021|338
Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: A randomized controlled trial
|Radiotherapy and Oncology|2012|321
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140